Enhances nitric oxide production, which supports endothelial and kidney function
A series of large-scale randomized controlled trials (RCTs) demonstrated that SGLT2i use reduced the risk of kidney disease progression in patients with and without diabetes ( post hoc analysis of SUSTAIN6 and PIONEER6 demonstrated that semaglutide slowed the eGFR decline in T2D patients with a high risk of CVD ( With combination therapy of SGLT2i and GLP1Ra, the preceding drug did not affect the renal outcome in the main analysis of RECAP study ( post hoc analysis, the SGLT2i-preceding group had a slower rate of eGFR decline in comparison to the GLP1Ra-preceding group, and multiple regression analysis identified the preceding of SGLT2i as an independent and significant factor of change in eGFR decline
Sulistyo, H., Kurniawan, D
Its triple agonist mechanism targeting GLP-1, GIP and glucagon receptors offer broader metabolic effects than earlier weight loss medications
If maximum weight loss is your priority and budget isnt a constraint, Mounjaro is the clear winner
The report also noted that a large Phase IIb trial (ZUPREME-1) is underway with enrolment expected to be completed in the first half of 2025 and that a second Phase IIb trial (ZUPREME-2) is planned to evaluate petrelintide in individuals with type 2 diabetes
